|
1
|
Nordenstedt H, White DL and El-Serag HB:
The changing pattern of epidemiology in hepatocellular carcinoma.
Dig Liver Dis. 42(Suppl 3): S206–S214. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Ferlay J, Shin HR, Bray F, Forman D,
Mathers C and Parkin DM: Estimates of worldwide burden of cancer in
2008: GLOBOCAN 2008. Int J Cancer. 127:2893–2917. 2010. View Article : Google Scholar
|
|
3
|
Parkin DM, Bray F, Ferlay J and Pisani P:
Global cancer statistics, 2002. CA Cancer J Clin. 55:74–108. 2005.
View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Yu MC and Yuan JM: Environmental factors
and risk for hepatocellular carcinoma. Gastroenterology. 127(Suppl
1): S72–S78. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Chuang SC, La Vecchia C and Boffetta P:
Liver cancer: Descriptive epidemiology and risk factors other than
HBV and HCV infection. Cancer Lett. 286:9–14. 2009. View Article : Google Scholar
|
|
6
|
Liang X, Bi S, Yang W, et al:
Epidemiological serosurvey of hepatitis B in China - declining HBV
prevalence due to hepatitis B vaccination. Vaccine. 27:6550–6557.
2009. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Liang H, Wang J, Xiao H, Wang D, Wei W,
Qiao Y and Boffetta P: Estimation of cancer incidence and mortality
attributable to alcohol drinking in China. BMC Public Health.
10:7302010. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Arsura M and Cavin LG: Nuclear
factor-kappaB and liver carcinogenesis. Cancer Lett. 229:157–169.
2005. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Pikarsky E, Porat RM, Stein I, Abramovitch
R, Amit S, Kasem S, Gutkovich-Pyest E, Urieli-Shoval S, Galun E and
Ben-Neriah Y: NF-kappaB functions as a tumour promoter in
inflammation-associated cancer. Nature. 431:461–466. 2004.
View Article : Google Scholar : PubMed/NCBI
|
|
10
|
He G and Karin M: NF-κB and STAT3 - key
players in liver inflammation and cancer. Cell Res. 21:159–168.
2011. View Article : Google Scholar
|
|
11
|
Berasain C, Castillo J, Perugorria MJ,
Latasa MU, Prieto J and Avila MA: Inflammation and liver cancer:
New molecular links. Ann NY Acad Sci. 1155:206–221. 2009.
View Article : Google Scholar
|
|
12
|
Baldwin AS Jr: Series introduction: The
transcription factor NF-kappaB and human disease. J Clin Invest.
107:3–6. 2001. View
Article : Google Scholar : PubMed/NCBI
|
|
13
|
Werner SL, Barken D and Hoffmann A:
Stimulus specificity of gene expression programs determined by
temporal control of IKK activity. Science. 309:1857–1861. 2005.
View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Curran JE, Weinstein SR and Griffiths LR:
Polymorphic variants of NFKB1 and its inhibitory protein NFKBIA,
and their involvement in sporadic breast cancer. Cancer Lett.
188:103–107. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Zhang P, Wei Q, Li X, Wang K, Zeng H, Bu H
and Li H: A functional insertion/deletion polymorphism in the
promoter region of the NFKB1 gene increases susceptibility for
prostate cancer. Cancer Genet Cytogenet. 191:73–77. 2009.
View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Lo SS, Chen JH, Wu CW and Lui WY:
Functional polymorphism of NFKB1 promoter may correlate to the
susceptibility of gastric cancer in aged patients. Surgery.
145:280–285. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Yu Y, Liu H, Jin M, Zhang M, Pan Y, Zhang
S, Li Q and Chen K: The joint association of REST and NFKB1
polymorphisms on the risk of colorectal cancer. Ann Hum Genet.
76:269–276. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Lin CW, Hsieh YS, Hsin CH, Su CW, Lin CH,
Wei LH, Yang SF and Chien MH: Effects of NFKB1 and NFKBIA gene
polymorphisms on susceptibility to environmental factors and the
clinicopathologic development of oral cancer. PLoS One.
7:e350782012. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Gao J, Xu HL, Gao S, et al: Genetic
polymorphism of NFKB1 and NFKBIA genes and liver cancer risk: A
nested case-control study in Shanghai, China. BMJ Open.
4:e0044272014. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Wang R: Two’s company, three’s a crowd:
Can H2S be the third endogenous gaseous transmitter?
FASEB J. 16:1792–1798. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Guidotti TL: Hydrogen sulfide: Advances in
understanding human toxicity. Int J Toxicol. 29:569–581. 2010.
View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Kilburn KH, Thrasher JD and Gray MR:
Low-level hydrogen sulfide and central nervous system dysfunction.
Toxicol Ind Health. 26:387–405. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Tan BH, Wong PT and Bian JS: Hydrogen
sulfide: A novel signaling molecule in the central nervous system.
Neurochem Int. 56:3–10. 2010. View Article : Google Scholar
|
|
24
|
Rong W, Kimura H and Grundy D: The
neurophysiology of hydrogen sulfide. Inflamm Allergy Drug Targets.
10:109–117. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Kamoun P: Endogenous production of
hydrogen sulfide in mammals. Amino Acids. 26:243–254. 2004.
View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Guo R, Wu K, Chen J, Mo L, Hua X, Zheng D,
Chen P, Chen G, Xu W and Feng J: Exogenous hydrogen sulfide
protects against doxorubicin-induced inflammation and cytotoxicity
by inhibiting p38MAPK/NFκB pathway in H9c2 cardiac cells. Cell
Physiol Biochem. 32:1668–1680. 2013.
|
|
27
|
Guo RM, Xu WM, Lin JC, Mo LQ, Hua XX, Chen
PX, Wu K, Zheng DD and Feng JQ: Activation of the p38 MAPK/NF-κB
pathway contributes to doxorubicin-induced inflammation and
cytotoxicity in H9c2 cardiac cells. Mol Med Rep. 8:603–608.
2013.PubMed/NCBI
|
|
28
|
El-Seweidy MM, Sadik NA and Shaker OG:
Role of sulfurous mineral water and sodium hydrosulfide as potent
inhibitors of fibrosis in the heart of diabetic rats. Arch Biochem
Biophys. 506:48–57. 2011. View Article : Google Scholar
|
|
29
|
Dong XB, Yang CT, Zheng DD, et al:
Inhibition of ROS-activated ERK1/2 pathway contributes to the
protection of H2S against chemical hypoxia-induced
injury in H9c2 cells. Mol Cell Biochem. 362:149–157. 2012.
View Article : Google Scholar
|
|
30
|
Yang Z, Yang C, Xiao L, Liao X, Lan A,
Wang X, Guo R, Chen P, Hu C and Feng J: Novel insights into the
role of HSP90 in cyto-protection of H2S against chemical
hypoxia-induced injury in H9c2 cardiac myocytes. Int J Mol Med.
28:397–403. 2011.PubMed/NCBI
|
|
31
|
Chen SL, Yang CT, Yang ZL, Guo RX, Meng
JL, Cui Y, Lan AP, Chen PX and Feng JQ: Hydrogen sulphide protects
H9c2 cells against chemical hypoxia-induced injury. Clin Exp
Pharmacol Physiol. 37:316–321. 2010. View Article : Google Scholar
|
|
32
|
Coletta C, Papapetropoulos A, Erdelyi K,
et al: Hydrogen sulfide and nitric oxide are mutually dependent in
the regulation of angiogenesis and endothelium-dependent
vasorelaxation. Proc Natl Acad Sci USA. 109:9161–9166. 2012.
View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Cai WJ, Wang MJ, Moore PK, Jin HM, Yao T
and Zhu YC: The novel proangiogenic effect of hydrogen sulfide is
dependent on Akt phosphorylation. Cardiovasc Res. 76:29–40. 2007.
View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Papapetropoulos A, Pyriochou A, Altaany Z,
et al: Hydrogen sulfide is an endogenous stimulator of
angiogenesis. Proc Natl Acad Sci USA. 106:21972–21977. 2009.
View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Kimura H: Hydrogen sulfide: From brain to
gut. Antioxid Redox Signal. 12:1111–1123. 2010. View Article : Google Scholar
|
|
36
|
Fiorucci S: Hydrogen sulfide: From
physiology to pharmacology. Inflamm Allergy Drug Targets. 10:77–84.
2011. View Article : Google Scholar : PubMed/NCBI
|
|
37
|
Hegde A and Bhatia M: Hydrogen sulfide in
inflammation: Friend or foe? Inflamm Allergy Drug Targets.
10:118–122. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
38
|
Zhang H and Bhatia M: Hydrogen sulfide: A
novel mediator of leukocyte activation. Immunopharmacol
Immunotoxicol. 30:631–645. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
39
|
Mok YY and Moore PK: Hydrogen sulphide is
pro-inflammatory in haemorrhagic shock. Inflamm Res. 57:512–518.
2008. View Article : Google Scholar : PubMed/NCBI
|
|
40
|
Gong QH, Wang Q, Pan LL, Liu XH, Huang H
and Zhu YZ: Hydrogen sulfide attenuates lipopolysaccharide-induced
cognitive impairment: A pro-inflammatory pathway in rats. Pharmacol
Biochem Behav. 96:52–58. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
41
|
Zhang J, Sio SW, Moochhala S and Bhatia M:
Role of hydrogen sulfide in severe burn injury-induced inflammation
in mice. Mol Med. 16:417–424. 2010.PubMed/NCBI
|
|
42
|
Szabo C, Coletta C, Chao C, Módis K,
Szczesny B, Papapetropoulos A and Hellmich MR: Tumor-derived
hydrogen sulfide, produced by cystathionine-β-synthase, stimulates
bioenergetics, cell proliferation, and angiogenesis in colon
cancer. Proc Natl Acad Sci USA. 110:12474–12479. 2013. View Article : Google Scholar
|
|
43
|
Pupo E, Pla AF, Avanzato D, Moccia F, Cruz
JE, Tanzi F, Merlino A, Mancardi D and Munaron L: Hydrogen sulfide
promotes calcium signals and migration in tumor-derived endothelial
cells. Free Radic Biol Med. 51:1765–1773. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
44
|
Du SX, Xiao J, Guan F, Sun LM, Wu WS, Tang
H, Du JB, Tang CS and Jin HF: Predictive role of cerebrospinal
fluid hydrogen sulfide in central nervous system leukemia. Chin Med
J (Engl). 124:3450–3454. 2011.
|
|
45
|
Levine J, Ellis CJ, Furne JK, Springfield
J and Levitt MD: Fecal hydrogen sulfide production in ulcerative
colitis. Am J Gastroenterol. 93:83–87. 1998. View Article : Google Scholar : PubMed/NCBI
|
|
46
|
Rose P, Moore PK, Ming SH, Nam OC,
Armstrong JS and Whiteman M: Hydrogen sulfide protects colon cancer
cells from chemopreventative agent beta-phenylethyl isothiocyanate
induced apoptosis. World J Gastroenterol. 11:3990–3997.
2005.PubMed/NCBI
|
|
47
|
Cai WJ, Wang MJ, Ju LH, Wang C and Zhu YC:
Hydrogen sulfide induces human colon cancer cell proliferation:
Role of Akt, ERK and p21. Cell Biol Int. 34:565–572. 2010.
View Article : Google Scholar : PubMed/NCBI
|
|
48
|
Cao Q, Zhang L, Yang G, Xu C and Wang R:
Butyrate-stimulated H2S production in colon cancer
cells. Antioxid Redox Signal. 12:1101–1109. 2010. View Article : Google Scholar
|
|
49
|
Ma K, Liu Y, Zhu Q, Liu CH, Duan JL, Tan
BK and Zhu YZ: H2S donor, S-propargyl-cysteine,
increases CSE in SGC-7901 and cancer-induced mice: Evidence for a
novel anti-cancer effect of endogenous H2S? PLoS One.
6:e205252011. View Article : Google Scholar
|
|
50
|
Murata T, Sato T, Kamoda T, Moriyama H,
Kumazawa Y and Hanada N: Differential susceptibility to hydrogen
sulfide-induced apoptosis between PHLDA1-overexpressing oral cancer
cell lines and oral keratinocytes: Role of PHLDA1 as an apoptosis
suppressor. Exp Cell Res. 320:247–257. 2014. View Article : Google Scholar
|
|
51
|
Chattopadhyay M, Kodela R, Olson KR and
Kashfi K: NOSH-aspirin (NBS-1120), a novel nitric oxide- and
hydrogen sulfide-releasing hybrid is a potent inhibitor of colon
cancer cell growth in vitro and in a xenograft mouse model. Biochem
Biophys Res Commun. 419:523–528. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
52
|
Lee ZW, Zhou J, Chen CS, Zhao Y, Tan CH,
Li L, Moore PK and Deng LW: The slow-releasing hydrogen sulfide
donor, GYY4137, exhibits novel anti-cancer effects in vitro and in
vivo. PLoS One. 6:e210772011. View Article : Google Scholar : PubMed/NCBI
|
|
53
|
Xu W, Wu W, Chen J, Guo R, Lin J, Liao X
and Feng J: Exogenous hydrogen sulfide protects H9c2 cardiac cells
against high glucose-induced injury by inhibiting the activities of
the p38 MAPK and ERK1/2 pathways. Int J Mol Med. 32:917–925.
2013.PubMed/NCBI
|
|
54
|
Kashfi K: Anti-cancer activity of new
designer hydrogen sulfide-donating hybrids. Antioxid Redox Signal.
20:831–846. 2014. View Article : Google Scholar :
|
|
55
|
Shi S, Li QS, Li H, Zhang L, Xu M, Cheng
JL, Peng CH, Xu CQ and Tian Y: Anti-apoptotic action of hydrogen
sulfide is associated with early JNK inhibition. Cell Biol Int.
33:1095–1101. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
56
|
Rinaldi L, Gobbi G, Pambianco M, Micheloni
C, Mirandola P and Vitale M: Hydrogen sulfide prevents apoptosis of
human PMN via inhibition of p38 and caspase 3. Lab Invest.
86:391–397. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
57
|
Holwerda KM, Burke SD, Faas MM, et al:
Hydrogen sulfide attenuates sFlt1-induced hypertension and renal
damage by upregulating vascular endothelial growth factor. J Am Soc
Nephrol. 25:717–725. 2014. View Article : Google Scholar :
|
|
58
|
Polhemus DJ, Kondo K, Bhushan S, Bir SC,
Kevil CG, Murohara T, Lefer DJ and Calvert JW: Hydrogen sulfide
attenuates cardiac dysfunction after heart failure via induction of
angiogenesis. Circ Heart Fail. 6:1077–1086. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
59
|
Köhn C, Dubrovska G, Huang Y and Gollasch
M: Hydrogen sulfide: Potent regulator of vascular tone and
stimulator of angiogenesis. Int J Biomed Sci. 8:81–86. 2012.
|
|
60
|
Bir SC, Kolluru GK, McCarthy P, Shen X,
Pardue S, Pattillo CB and Kevil CG: Hydrogen sulfide stimulates
ischemic vascular remodeling through nitric oxide synthase and
nitrite reduction activity regulating hypoxia-inducible factor-1α
and vascular endothelial growth factor-dependent angiogenesis. J Am
Heart Assoc. 1:e0040932012. View Article : Google Scholar
|
|
61
|
Tao BB, Liu SY, Zhang CC, et al: VEGFR2
functions as an H2S-targeting receptor protein kinase
with its novel Cys1045-Cys1024 disulfide bond serving as a specific
molecular switch for hydrogen sulfide actions in vascular
endothelial cells. Antioxid Redox Signal. 19:448–464. 2013.
View Article : Google Scholar :
|
|
62
|
Leung WK, To KF, Go MY, Chan KK, Chan FK,
Ng EK, Chung SC and Sung JJ: Cyclooxygenase-2 upregulates vascular
endothelial growth factor expression and angiogenesis in human
gastric carcinoma. Int J Oncol. 23:1317–1322. 2003.PubMed/NCBI
|
|
63
|
Jones JL, Shaw JA, Pringle JH and Walker
RA: Primary breast myoepithelial cells exert an invasion-suppressor
effect on breast cancer cells via paracrine down-regulation of MMP
expression in fibroblasts and tumour cells. J Pathol. 201:562–572.
2003. View Article : Google Scholar : PubMed/NCBI
|
|
64
|
Li C, Li F, Zhao K, Yao J, Cheng Y, Zhao
L, Li Z, Lu N and Guo Q: LFG-500 inhibits the invasion of cancer
cells via downregulation of PI3K/AKT/NF-κB signaling pathway. PLoS
One. 9:e913322014. View Article : Google Scholar
|
|
65
|
Puzovic V, Brcic I, Ranogajec I and
Jakic-Razumovic J: Prognostic values of ETS-1, MMP-2 and MMP-9
expression and co-expression in breast cancer patients. Neoplasma.
61:439–446. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
66
|
Ruan M, Zhang Z, Li S, Yan M, Liu S, Yang
W, Wang L and Zhang C: Activation of Toll-like receptor-9 promotes
cellular migration via up-regulating MMP-2 expression in oral
squamous cell carcinoma. PLoS One. 9:e927482014. View Article : Google Scholar : PubMed/NCBI
|
|
67
|
Li Y, Liu G, Cai D, Pan B, Lin Y, Li X, Li
S, Zhu L, Liao X and Wang H: H2S inhibition of chemical
hypoxia-induced proliferation of HPASMCs is mediated by the
upregulation of COX-2/PGI2. Int J Mol Med. 33:359–366. 2014.
|
|
68
|
Ang SF, Sio SW, Moochhala SM, MacAry PA
and Bhatia M: Hydrogen sulfide upregulates cyclooxygenase-2 and
prostaglandin E metabolite in sepsis-evoked acute lung injury via
transient receptor potential vanilloid type 1 channel activation. J
Immunol. 187:4778–4787. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
69
|
Terzuoli E, Meini S, Cucchi P, Catalani C,
Cialdai C, Maggi CA, Giachetti A, Ziche M and Donnini S: Antagonism
of bradykinin B2 receptor prevents inflammatory responses in human
endothelial cells by quenching the NF-κB pathway activation. PLoS
One. 9:e843582014. View Article : Google Scholar
|
|
70
|
Tsagaraki I, Phenekos C, Tsilibary E and
Tzinia A: Calcitonin-induced NF-κB activation up-regulates
fibronectin expression in MG63 osteosarcoma cells. Anticancer Res.
33:4901–4906. 2013.PubMed/NCBI
|
|
71
|
Hsu CJ, Wu MH, Chen CY, Tsai CH, Hsu HC
and Tang CH: AMP-activated protein kinase activation mediates
CCL3-induced cell migration and matrix metalloproteinase-2
expression in human chondrosarcoma. Cell Commun Signal. 11:682013.
View Article : Google Scholar : PubMed/NCBI
|
|
72
|
Son SW, Kim HG, Han JM, Lee JS, Choi MK,
Lee JS and Son CG: Anti-melanoma activity of Cynanchi atrati Radix
is mediated by regulation of NF-kappa B activity and pro-apoptotic
proteins. J Ethnopharmacol. 153:250–257. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
73
|
Jana D, Sarkar DK, Ganguly S, Saha S, Sa
G, Manna AK, Banerjee A and Mandal S: Role of cyclooxygenase 2
(COX-2) in prognosis of breast cancer. Indian J Surg Oncol.
5:59–65. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
74
|
Wu X, Cai M, Ji F and Lou LM: The impact
of COX-2 on invasion of osteosarcoma cell and its mechanism of
regulation. Cancer Cell Int. 14:272014. View Article : Google Scholar : PubMed/NCBI
|
|
75
|
Xu K, Wang L and Shu HK: COX-2
overexpression increases malignant potential of human glioma cells
through Id1. Oncotarget. 5:1241–1252. 2014.PubMed/NCBI
|
|
76
|
Dong X, Li R, Xiu P, et al: Meloxicam
executes its antitumor effects against hepatocellular carcinoma in
COX-2-dependent and -independent pathways. PLoS One. 9:e928642014.
View Article : Google Scholar
|
|
77
|
Tegeder I, Niederberger E, Israr E,
Gühring H, Brune K, Euchenhofer C, Grösch S and Geisslinger G:
Inhibition of NF-kappaB and AP-1 activation by R- and
S-flurbiprofen. FASEB J. 15:2–4. 2001.
|
|
78
|
Seo KW, Coh YR, Rebhun RB, et al:
Antitumor effects of celecoxib in COX-2 expressing and
non-expressing canine melanoma cell lines. Res Vet Sci. pii:
S0034–5288. 00051–00054. 2014.
|
|
79
|
Sui W, Zhang Y, Wang Z, Wang Z, Jia Q, Wu
L and Zhang W: Antitumor effect of a selective COX-2 inhibitor,
celecoxib, may be attributed to angiogenesis inhibition through
modulating the PTEN/PI3K/Akt/HIF-1 pathway in an H22 murine
hepatocarcinoma model. Oncol Rep. 31:2252–2260. 2014.PubMed/NCBI
|
